BPC-157 + TB-500: Why This Stack Works and How to Run It

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Its primary mechanism is angiogenesis promotion at the site of administration - it upregulates VEGFR2 signaling to drive new blood vessel formation into damaged tissue. Secondary pathways include tendon fibroblast proliferation (via FGFR2), collagen synthesis via TGF-β upregulation, and a direct anti-inflammatory effect through modulation of the nitric oxide system.

Critically, BPC-157's effects are primarily local. Subcutaneous injection near a target tissue concentrates its angiogenic action at that site. Studies in rodent models demonstrate measurable tendon, ligament, and muscle repair within 7–14 days at 200–500 mcg/day doses.

TB-500 is a synthetic fragment of Thymosin Beta-4 spanning residues 17–23 (the LKKTET actin-binding domain). Note: Ac-SDKP is a distinct tetrapeptide fragment of Thymosin Alpha-1, not Thymosin Beta-4 — the two should not be conflated. TB-500 contains the actin-binding domain responsible for TB4's regenerative effects. Its mechanism is fundamentally different from BPC-157: rather than promoting local angiogenesis, TB-500 works by sequestering monomeric G-actin - the building block of intracellular actin filaments - which modulates cell migration, differentiation, and wound healing across multiple tissue types simultaneously.

This gives TB-500 a systemic reach that BPC-157 lacks. A single subcutaneous injection distributes throughout the body, with particularly elevated uptake in muscle, connective tissue, and cardiac tissue. Plasma half-life is short (~1.2–1.5 hours), but tissue residence time is substantially longer - likely explaining the efficacy of twice-weekly dosing despite rapid clearance.

The standard loading protocol for BPC-157 is 500 mcg/day for 4–6 weeks, followed by 250 mcg/day maintenance if continuing. TB-500's loading phase is 2.5 mg twice weekly for 4–6 weeks, dropping to 2.5 mg once monthly for maintenance. The loading phase is where the most significant tissue repair signal is established - maintenance doses are designed to sustain, not rebuild.

Both compounds are typically run concurrently for the full loading phase. There is no pharmacokinetic interaction between them - BPC-157 and TB-500 work on different receptor systems and can be drawn separately and injected at the same time or at different times without consequence.